

## Enrique Grande Pulido MD., Msc., PhD



### Enrique Grande Pulido MD, Msc., PhD

PROFESSOR

Renal cancer specialist.

Enrique Grande, MD., Msc., PhD., has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. He is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. He was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a Master's degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). He has published as author more than 150 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Professor at the Francisco de Vitoria University, editor of several international journals. Dr Grande has participated in the most recent trials in the field of RCC that led to the approval of the new drugs we have now available.

**Full name:** Enrique Grande Pulido

**Country:** Spain

**Current Position:**

2017 – present	Head of Oncology Department at MD Anderson Cancer Center Madrid.
2017 – present	Director of Clinical Research at MD Anderson Cancer Center Madrid.
2010 – present	Expert Advisor of the Spanish Medicines and Sanitary Products Agency (AEMPS).
2010 – present	Member of the Directory Board of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
2012 – 2017	Director of Clinical and Translational Research of the Medical Oncology Service at Ramon y Cajal University Hospital.
2012 – 2017	Director of Clinical Associated Unit (UCA) to CNIO at Ramon y Cajal University Hospital.

**Education:**

2013	Doctorate in Medicine (PhD) at the University of Alcalá with mention of "Cum Laude".
2011 - 2012	Master (Msc) in Oncology Molecular Biology at the National Center for Research in Oncology (CNIO)
2005	Degree of Bachelor's in medicine-Advanced Study Accreditation (DEA) degree obtained at Universidad Complutense de Madrid.
2001 - 2005	Medical Oncology training program completed at Hospital Clínico San Carlos, Madrid, under the direction of Prof. Eduardo Díaz-Rubio.
2000	Spanish fellowship/residency access examination: passed on April 2000
1993 - 1999	Medical School: Graduate in Medicine from the Universidad Autónoma of Madrid

**Experience:**

2017 – present	Head of Oncology Department at MD Anderson Cancer Center Madrid.
2017 – present	Director of Clinical Research at MD Anderson Cancer Center Madrid.
2013 – 2015	Bladder Cancer Clinical Program Lead at CNIO, España.
2010 – 2017	Honoric Professor at Universidad de Alcalá

**Scientific publications:**

Number of publications as author or co-author: 194

Book chapters: 14

Recent publications:

Evaluating radiological response in pancreatic neuroendocrine tumors treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET\_ GETNE1504 study). Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, Alonso Gordo T, Nuñez-Valdovino B, Sanchez Canovas M, Matos I, Alonso V, Lopez C, Viudez A, Izquierdo M, Calvo-Temprano D, Grande E, Capdevila J, Jimenez-Fonseca P. Br J Cancer. 2019 Sep 3. doi: 10.1038/s41416-019-0558-7.

Prediction of Progression-Free Survival in Patients with Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated with a Somatostatin Analog: The GETNETRASGU Study. Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordo T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C,

Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R. *J Clin Oncol*. 2019 Aug 7;JCO1900980. doi: 10.1200/JCO.19.00980.

Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Capdevila J, Hernando J, Perez-Hoyos S, Román Gonzalez A, Grande E. *Oncologist*. 2019 Jul 22. pii: theoncologist.2018-0675. doi: 10.1634/theoncologist.2018-0675.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodríguez-Garrote M, Calvo A, Grande E, Aranda E. *BMC Cancer*. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7

On professionalism in the management of thyroid tumors and multidisciplinary working groups (reply letter). Díez JJ, Galofré JC, Oleaga A, Grande E, Mitjavila M, Moreno P. *Endocrinol Diabetes Nutr*. 2019 May 15. pii: S2530-0164(19)30108-9. doi: 10.1016/j.endinu.2019.03.012.